Pàgina inicial > Resultats de la cerca: Goodman, Shaun G.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
9 p, 627.4 KB Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial / White, Harvey D. (Auckland City Hospital) ; Gabriel Steg, P. (Royal Brompton Hospital (Londres)) ; Szarek, Michael (SUNY Downstate Medical Center School of Public Health) ; Bhatt, Deepak L (Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Diaz, Rafael (Instituto Cardiovascular de Rosario) ; Edelberg, Jay M. (Sanofi) ; Erglis, Andrejs (University of Latvia) ; Goodman, Shaun G. (University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, Robert A. (Department of Medicine) ; Wouter Jukema, J. (Leiden University Medical Center) ; Lopes, Renato D. (Duke Clinical Research Institute) ; Mahaffey, Kenneth W. (Stanford University School of Medicine) ; Moryusef, Angele (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals) ; Roe, Matthew T. (Duke Clinical Research Institute) ; Sritara, Piyamitr (Mahidol University) ; Tricoci, Pierluigi (CSL Behring) ; Zeiher, Andreas Michael (Goethe University) ; Schwartz, Gregory G. (University of Colorado School of Medicine) ; Cequier Fillat, Angel R. (hospital Universitari de Bellvitge) ; Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ; Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. [...]
2019 - 10.1093/eurheartj/ehz299
European heart journal, Vol. 40 Núm. 33 (january 2019) , p. 2801-2809  
Registre complet - Creative Commons
2.
10 p, 396.0 KB Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial / Szarek, Michael (State University of New York) ; White, Harvey D. (University of Auckland and Green Lane Cardiovascular Services Auckland City Hospital) ; Schwartz, Gregory G. (Division of Cardiology. University of Colorado School of Medicine) ; Alings, Marco (Amphia Ziekenhuis Molengracht) ; Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Chiang, Chern-En (Taipei Veterans General Hospital and National Yang-Ming University) ; Diaz, Rafael (Instituto Cardiovascular de Rosario) ; Edelberg, Jay M. (Sanofi) ; Goodman, Shaun G. (University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, R.A. (Stanford University) ; Jukema, J.Wouter (Leiden University Medical Center) ; Kimura, Takeshi (Kyoto University Graduate School of Medicine) ; Kiss, Robert Gabor (Magyar Honvédség Egészségügyi Központ) ; Lecorps, Guillaume (Sanofi) ; Mahaffey, Kenneth W. (Stanford University) ; Moryusef, Angèle (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals Inc.) ; Roe, Matthew T. (Duke University Medical Center) ; Tricoci, Pierluigi (Duke University Medical Center) ; Xavier, Denis (St. John's Medical College and Research Institute) ; Zeiher, Andreas Michael (Goethe University) ; Steg, Ph Gabriel (Royal Brompton Hospital (Londres)) ; Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ; Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ; Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. [...]
2019 - 10.1016/j.jacc.2018.10.039
Journal of the American College of Cardiology, Vol. 73 Núm. 4 (may 2019) , p. 387-396  
Registre complet - Creative Commons
3.
10 p, 324.1 KB Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial / Jukema, J.Wouter (Leiden University Medical Center) ; Szarek, Michael (State University of New York) ; Zijlstra, Laurien E. (Leiden University Medical Center) ; de Silva, H.Asita (University of Kelaniya) ; Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Diaz, Rafael (Cardiovascular Institute of Rosario) ; Edelberg, Jay M. (Sanofi) ; Goodman, Shaun G. (St. Michael's Hospital. University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, Robert A. (Stanford University) ; Karpov, Yuri (Russian Cardiological Scientific-Productive Complex) ; Moryusef, Angèle (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals. Inc.) ; Prieto, Juan C. (University of Chile Clinical Hospital) ; Roe, Matthew T. (Duke University School of Medicine) ; White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ; Zeiher, Andreas Michael (Goethe University) ; Schwartz, Gregory G. (University of Colorado School of Medicine) ; Steg, P.Gabriel (Royal Brompton Hospital (Londres)) ; Cequier, Ángel (Hospital Universitari de Bellvitge) ; García-Dorado, David (Hospital Universitari Vall d'Hebron) ; Mata Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. [...]
2019 - 10.1016/j.jacc.2019.03.013
Journal of the American College of Cardiology, Vol. 74 Núm. 9 (march 2019) , p. 1167-1176  
Registre complet - Creative Commons
4.
12 p, 648.4 KB Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome / Bittner, Vera A. (University of Alabama at Birmingham) ; Szarek, Michael (State University of New York) ; Aylward, Philip (South Australian Health and Medical Research Institute) ; Bhatt, Deepak L. (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ; Díaz, Rafaël J. (Instituto Cardiovascular de Rosario) ; Edelberg, Jay M. (Sanofi) ; Fras, Zlatko (Univerza V Ljubljani) ; Goodman, Shaun G. (University of Toronto) ; Halvorsen, Sigrun (University of Oslo) ; Hanotin, Corinne (Sanofi) ; Harrington, Robert A. (Stanford University) ; Jukema, J. Wouter (Leiden University Medical Center) ; Loizeau, Virginie (Sanofi) ; Moriarty, Patrick Maurice (University of Kansas Medical Center) ; Moryusef, Angèle (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals Inc.) ; Roe, Matthew T. (Duke University School of Medicine) ; Sinnaeve, Peter (University of Leuven) ; Tsimikas, Sotirios (University of California San Diego) ; Vogel, Robert A. (University of Colorado School of Medicine) ; White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ; Zahger, Doron (Soroka University Medical Center) ; Zeiher, Andreas Michael (Goethe University) ; Steg, Philippe Gabriel (Royal Brompton Hospital (Londres)) ; Schwartz, Gregory G. (University of Colorado School of Medicine) ; Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Cequier, Ángel (Hospital Universitari de Bellvitge) ; García-Dorado, David (Hospital Universitari Vall d'Hebron) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Universitat Autònoma de Barcelona
Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). [...]
2020 - 10.1016/j.jacc.2019.10.057
Journal of the American College of Cardiology, Vol. 75 Núm. 2 (21 2020) , p. 133-144  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
3 Goodman, S.G.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem